Oak Hill Bio

Executive Summary

Oak Hill Bio is a clinical-stage biotechnology company focused on acquiring and developing life-changing rare disease therapeutics. Their pipeline includes three late-stage clinical programs: a treatment for Angelman syndrome (Phase 2/3), a therapy for complications of extremely premature birth (Phase 2), and a preclinical candidate for diabetic macular edema. The company employs a strategy of in-licensing and advancing assets with proven mechanisms, reducing early-stage risk. With operations in the US and UK, Oak Hill Bio aims to address significant unmet medical needs in rare diseases. The company's lead program for Angelman syndrome, a severe neurodevelopmental disorder, has the potential to be a first-in-class therapy. Recent progress includes positive interim data from Phase 2 studies. The company is well-positioned to deliver key milestones over the next 12-18 months.

Upcoming Catalysts (preview)

• Q2 2026Phase 2/3 data readout for Angelman syndrome candidate60% success
• Q4 2026Phase 2 results for extremely premature birth complications50% success
• TBDPotential partnership or licensing deal for diabetic macular edema program40% success